A new experimental drug that disables the antioxidant defense PRX3 controlled disease progression in 67% of mesothelioma patients in an early clinical trial, offering hope for a cancer with few effective treatments.
Experimental Drug Turns Mesothelioma's Defenses Against It
A new experimental drug that disables the antioxidant defense PRX3 controlled disease progression in 67% of mesothelioma patients in an early clinical trial, offering hope for a cancer with few effective treatments.
Mesothelioma · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.